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Abstract Renal dysfunction is common in clinical settings in
which cardiac function is compromised such as heart failure,
cardiac surgery or sepsis, and is associated with high morbidity
and mortality. Levosimendan is a calcium sensitizer and potas-
sium channel opener used in the treatment of acute heart failure.
This review describes the effects of the inodilator levosimendan
on renal function. A panel of 25 scientists and clinicians from 15
European countries (Austria, Finland, France, Hungary, Germa-
ny, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain,
Sweden, Turkey, the United Kingdom, and Ukraine) convened
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and reached a consensus on the current interpretation of the renal
effects of levosimendan described both in non-clinical research
and in clinical study reports. Most reports on the effect of
levosimendan indicate an improvement of renal function in heart
failure, sepsis and cardiac surgery settings. However, caution
should be applied as study designs differed from randomized,
controlled studies to uncontrolled ones. Importantly, in the largest
HF study (REVIVE I and II) no significant changes in the renal
functionwere detected. As it regards themechanism of action, the
opening of mitochondrial KATP channels by levosimendan is
involved through a preconditioning effect. There is a strong
rationale for randomized controlled trials seeking beneficial renal
effects of levosimendan. As an example, a study is shortly to
commence to assess the role of levosimendan for the prevention
of acute organ dysfunction in sepsis (LeoPARDS).
Keywords Levosimendan . Renal dysfunction
Abbreviations
HF Heart failure
AHF Acute heart failure
GFR Glomerular filtration rate
eGFR Estimated glomerular filtration rate
NYHA New York Heart Association class




L-NAME Nω-nitro-L-arginine methyl ester
5-HD 5-hydroxydecanoate
RBF Renal blood flow
CABG Coronary artery bypass grafting
MAP Mean arterial pressure
RPV Renal parenchymal volume
Introduction
Renal dysfunction is common in patients with heart failure
(HF) [1] and other clinical settings in which cardiac function is
compromised such as cardiac surgery or sepsis [2, 3] and is
associated with high morbidity and mortality. Due to the
complex interactions underlying this cardiorenal syndrome,
the kidneys can be affected in both the short- and long-term.
Elevations of serum urea and creatinine levels are often en-
countered in congestive HF, secondary to reductions in renal
blood flow and/or elevations in central venous pressure lead-
ing to a reduction in glomerular filtration rate (GFR). Con-
versely, impaired renal function has a significant impact on the
prognosis of patients with compromised heart function. For
instance, in a broad spectrum of patients with chronic HF in
the CHARM study [4], renal dysfunction was independently
associated with increased risk of death, cardiovascular death,
and hospitalization due to HF. In advanced chronic HF, renal
impairment was a stronger predictor of mortality than either
left ventricular ejection fraction or New York Heart Associa-
tion class [5].
Levosimendan is a calcium sensitizer and adenosine
triphosphate-dependent potassium (KATP) channel opener de-
veloped for treating acute HF. Its positive inotropic,
vasodilating and cardioprotective properties have been exten-
sively investigated in experimental studies [6] and clinical
trials [7] not only in the context of HF but also in surgery
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settings and in critical care patients. Levosimendan increases
myocardial contractility, reduces filling pressure, and dilates
arterial, venous and coronary vessels [6]. In contrast to other
inotropic agents, the enhanced cardiac contractility seen with
levosimendan is not accompanied by large increases in oxy-
gen consumption [8]. Levosimendan has an active metabolite,
OR-1896, that has similar pharmacological properties to
levosimendan. As this metabolite is formed and eliminated
slowly, it offers at least 7 days of added benefit [9].
This paper examines available data on the effect of
levosimendan on renal function also in comparison with other
available inotropes and vasodilators.
Methods
In the systematic analysis of the literature data sources
were PubMed, Index Medicus, Excerpta Medica, Refer-
ence Update, BIOSIS, Science Citation Index. Pertinent
papers were independently identified by two trained
investigators (updated October 20, 2012). Papers and
abstracts found by searching (levosimendan AND (renal
OR kidney*)) were selected according to the search
strategy described in Figure 1. For the synthesis of the
data a panel of 25 scientists and clinicians from 15
European countries (Austria, Finland, France, Hungary, Ger-
many, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain,
Sweden, Turkey, the United Kingdom, and Ukraine) convened
onOctober 25, 2012. Themembers of the panel were invited on
the basis of their authorship of scientific papers which described
the renal effects of levosimendan. Even if a paper did describe
neutral or negative effects the first author was invited to attend
and discuss his/her data. The panel reached a consensus on the
current interpretation of the renal effects of levosimendan and
its putative mechanisms of action.
Evidence from Animal Models
Pre-clinical data on renal perfusion effects are scant and some-
times contradictory (Table 1). In healthy dogs, levosimendan
increased renal medullary blood flow [10], yet did not affect
either the renal macro- or the micro-circulation under septic
conditions in pigs and rabbits [11, 12]. In these studies,
levosimendan improved cardiac function but also reduced arterial
blood pressure; both of these factors will influence renal perfu-
sion. Grossini et al. [13] investigated the renal effects of
levosimendan in anesthetized pigs undergoing an ischemia-
reperfusion injury, under conditions of ‘renal isolation’. Here,
direct administration into the renal artery during 90 min of
ischemia did not influence the subsequent change in renal blood
flow on reperfusion [13].
The rationale for the use of levosimendan in
lipopolysaccharide-induced acute renal failure was the as-
sumption that calcium sensitization specifically offsets
sepsis-induced reductions in myocardial function, and thus
improves systemic and renal hemodynamics and mitigates
the lipopolysaccharide-induced inflammatory state. Studies
in endotoxemic mice [14] and ovine septic shock [15] found
beneficial renal effects in conjunction with improved hemody-
namics rather than immunomodulation [14]. In an endotoxemic
pig model, where levosimendan did not improve hemodynam-
ics, no beneficial effects on renal function were observed [15].
These findings are, however, not consistent.
In a study of porcine endotoxemia levosimendan markedly
improved cardiac output and splanchnic but not renal blood
flow [12].
Ischemia-reperfusion (I/R) injury in the kidneys is a signif-
icant problem in critically ill patients, e.g. after hemorrhage
and/or trauma, as it is an important cause of acute renal failure
due to oxidative, inflammatory and apoptotic mechanisms. I/
R injury can result in the development of a marked systemic
inflammatory response and multiple organ dysfunction,
49 abstracts were retrieved from 
databases searches and additional
hints 
1 duplicate publication
48 articles eligible for inclusion and  
detailed assessment by the expert 
panel
22 articles excluded because not 
describing data on renal effects or 
markers, or because retrospective 
analyses  
27articles  finally included in the 
systematic review
6 articles added by the expert panel
during the final discussion 
5 articles excluded during revision 
because editorials or case reports 
Fig. 1 Flow diagram for
selection of the articles included
in this systematic review
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leading to an approximate 30-40 % mortality rate [16, 17].
The anti-inflammatory and anti-apoptotic properties of
levosimendan make it an interesting candidate for treatment
of this condition. Indeed it has provided protection through a
preconditioning effect [18–20] and a reduction in inflamma-
tory and oxidative stress profiles [21, 22]. In a rabbit renal I/
R injury model, a levosimendan infusion commenced 30-
min pre-ischaemia provided similar renal protection as
iloprost against oxidative stress [23]. Likewise, in a pig
model, levosimendan infused into the renal artery during
90 min of ischemia followed by 120-min of reperfusion
provided renal protection with a reduction in renal damage
(N-acetyl-β-glucosaminidase [NAG]), oxidative stress
(malonyldialdehyde) and apoptosis [13]. Renal function
was preserved to a higher degree, and cell survival and
antioxidant systems were activated to a greater extent. These
benefits could be prevented by pre-treatment with the non-
specific nitric oxide synthase blocker, Nω-nitro-L-arginine
methyl ester (L-NAME), or with the mitochondrial KATP
channel inhibitor, 5-hydroxydecanoate (5-HD). Finally, using
a model of salt-sensitive hypertensive Dahl/Rapp rats, the
levosimendan metabolite OR-1896 prevented salt-induced
cardiovascular mortality and ameliorated cardiac hypertrophy
and function, but without providing any significant renal
protection [24].
Consensus Opinion on Current Preclinical Data
Regarding Renal Effects of Levosimendan
Data obtained in pre-clinical studies suggest that the anti-oxidant
and anti-apoptotic effects of levosimendan could be related to
protection against renal ischemic reperfusion injury. As seen in
the cardiac muscle, the opening of the mitochondrial KATP
channels may be involved through a preconditioning effect,
and nitric oxide may play a significant role. All in all, animal
data on the effect of Levosimendan on renal function are not
consistent. In fact, experimental data obtained in different renal
injurymodels are quite different, but are still consistent within the
individual models. In septic models there seems to be predomi-
nant improvements in hemodynamics by levosimendan, whereas
the organ-protective effect of the drug dominates in case of I/R
injury. It should be noted there are no experimental data on renal
effects in animal models of heart failure. Animal data on the
Table 1 Effects of levosimendan or its metabolite OR-1896 on renal tissue and/or function in in vivo animal experiments
Study Animal
model
Disease model Comparator Main levosimendan effects on renal tissue and/or function
Grossini [13] Pig Renal I/R Levosimendan without or
with Custodiol® vs
placebo
Better protection against renal I/R injury in terms of
antioxidant, anti-apoptotic and pro-survival actions, and
improvement of renal function (creatinine clearance, plasma
creatinine, microalbuminuria, albumin/creatinine ratio). Role
of mitochondrial KATP channels and NO
Rehberg [42] Sheep Sepsis Vasopressin and
norepinephrine ±
levosimendan
Improved renal function (surrogate parameters: creatinine,
plasma urea, dieresis, urinary protein/creatinine ratio)
Yakut [23] Rabbit Renal I/R Levosimendan vs placebo
or iloprost
More pronounced reduction in renal I/R injury
Zager [14] Mouse Endotoxemic
acute renal
failure
Levosimendan vs placebo Protection against endotoxemic acute renal failure due to
vasoactive effects
Faivre [11] Rabbit Sepsis Levosimendan with vasopressin
vs levosimendan with
norepinephrine
No altered systolic or diastolic renal blood flow or cortical or
medullary perfusion
Oldner [12] Pig Sepsis Levosimendan vs placebo Renal blood flow unaffected
Pagel [10] Dog Healthy Levosimendan vs
pimobendan or milrinone
Greater increase in blood flow to the renal medulla and
decreased
renal medullary and cortical vascular resistance









OR 1896 vs placebo No effects on albuminuria or tissue morphology
Chew [51] Pig Sepsis Levosimendan vs placebo No effects on renal and liver function (serum creatinine, urea,
bilirubin, AST, ALT)
I/R ischemia/reperfusion; Custodiol® multi-organ histidine-tryptophan-ketoglutarate preservation solution; NO nitric oxide; AST aspartate aminotrans-
ferase; ALT alanine aminotransferase
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effect of levosimendan on renal function do not provide defini-
tive evidence as to whether the observed reno-protective effects




Renal effects of levosimendan have been evaluated in several
clinical studies in patients with severe systolic HF. The LIDO
randomized controlled trial compared levosimendan and
dobutamine in patients with low-output HF [25]. Apart from
an overall clinical outcome benefit, renal function (defined as
a decrease in serum creatinine) improved over 24 h in the
levosimendan arm, as compared to the control group (−9
and −1 μM/l, respectively, p=0,03). In parallel, the non-
randomized PORTLAND study assessed the efficacy and
safety of levosimendan in the treatment of acute HF in every-
day clinical practice [26]. Diuresis rapidly improved in previ-
ously oliguric patients after initiation of levosimendan, along
with a reduction in serum creatinine levels that persisted on
day five.Wemust highlight, however, that in the PORTLAND
study there was not a control arm.
In a single-centre prospective study of patients with ad-
vanced chronicHFawaiting cardiac transplantation, at 3months
there was significant improvement in creatinine clearance in the
levosimendan arm, with little or no change in the control group
[27]. A fall in serum creatinine levels ≥0.5 mg/dL occurred in
50 % of levosimendan patients, compared to 10 % of controls
(p=0.005).
Yilmaz et al. [28] investigated 88 consecutive patients with
acutely decompensated HF (NYHA III-IV) who required ino-
tropic therapy. Patients were randomized to receive either
levosimendan or dobutamine. While left ventricular ejection
fraction increased significantly in both treatment groups, the
levosimendan group showed significant improvement in GFR
after 24 h (+15.3 %), while the dobutamine arm showed no
difference (−1.33 %). At 72 h, GFR was significantly increased
from baseline levels in levosimendan- (+45.45 %), but not in
dobutamine- (+0.09 %) treated patients, although both drugs
improved 24-h urinary output. The same group also compared
the effects of levosimendan and dobutamine on right ventricular
function in 40 consecutive patients with severe chronic
biventricular HF [29]. Again, levosimendan improved both
24-h urine output and creatinine levels, whereas dobutamine
produced only a small increase in urine output and no improve-
ment in creatinine levels. Levosimendan patients also required
less diuretic therapy and were discharged sooner.
Zorlu et al. [30] studied the effect of levosimendan in
patients with severe systolic heart failure and worsening renal
function and subclassified the patients into those without and
with worsening renal function, defined as an increase in serum
creatinine >0.3 mg/dL. Levosimendan significantly improved
renal function (creatinine, GFR) in those with worsening renal
function but not in those with stable renal function.
Finally, Caira et al. [31] showed that levosimendan im-
proves renal function, systemic and renal hemodynamic pa-
rameters in patients with acute heart failure andmoderate renal
impairment by measuring renal blood flow, glomerular filtra-
tion rate, blood urea nitrogen, creatinine, urinary output, so-
dium excretion and plasma sodium.
During a late revision of this text the results of the phase III
studies REVIVE I and II were published [32] containing
further data on the effect of levosimendan on renal function:
worsening of renal function occurred in 12/350 patients in the
levosimendan arms, and 16/350 patients in the placebo arm
(n.s.), thus no significant improvement of renal function was
found.
Cardiac Surgery
A limited number of clinical studies assessed the renal effects
of levosimendan in the context of cardiac surgery. Bragadottir
et al. [33] investigated the short-term effects of levosimendan
on renal blood flow, GFR, renal oxygen consumption, and
oxygenation in 30 patients with normal preoperative serum
creatinine levels after uncomplicated surgery. Compared to
placebo, levosimendan increased cardiac output, promoted
renal vasodilatation and increased renal blood flow and
GFR, suggestive of selective dilatation of pre-glomerular re-
sistance vessels. The renal oxygen supply–demand relation-
ship was however unaffected.
Levosimendan facilitated the weaning from the cardiopul-
monary bypass in a placebo-controlled study in 60 patients
with left ventricular ejection fraction <50 % undergoing cor-
onary artery bypass grafting surgery [34]. In a substudy of the
same population the postoperative renal function was assessed
[35] and no significant differences between levosimendan and
placebo groups were detected in terms of creatinine, cystatin C
and urine N-acetyl-β-glucosaminidase (NAG). Eight (26.6 %)
levosimendan patients and 13 (43.3 %) placebo patients ex-
perienced renal incidents (as defined by the authors), though
this difference did not reach statistical significance (p=0.167).
Four additional studies on the use of levosimendan in cardi-
ac surgery included some benefits on renal endpoints (mainly
postoperative renal dysfunction or failure). Al-Shawaf et al.
[36] studied type 2 diabetic patients with depressed myocardial
function who underwent elective surgery for coronary artery
disease. Among the postoperative events, renal dysfunction
was noticed in 2/14 patients treated with levosimendan vs 5/
16 patients treated with milrinone. Alvarez et al. [37] compared
levosimendan to dobutamine in cardiac surgery patients devel-
oping low cardiac output syndrome. The authors reported 1/15
renal failure in the levosimendan group vs 0/15 in the
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comparator group. Barisin et al. [38] did not notice any post-
operative acute renal failure event in either the levosimendan or
placebo arm when the treatment was administered preopera-
tively in patients undergoing off-pump CABG. Finally, Levin
et al. [39] reported 5/69 and 21/68 episodes of renal failure in
the levosimendan and dobutamine arms of their randomized
study on the treatment of patients who develop post-operative
low cardiac output syndrome after CABG with cardiopulmo-
nary bypass. The data of these four studies are summarized in a
recent meta-analysis by Landoni et al. [7].
Sepsis
A study by Morelli et al. reports data on the renal effect of
levosimendan in septic patients. [40] Patients with persisting left
ventricular dysfunction related to septic shock after 48 h of
conventional treatment including dobutamine (5 μg/kg per min-
ute) were randomized after 48 h of conventional treatment to
receive a 24-h infusion of either levosimendan (0.2 μg/kg per
min, n=15) or dobutamine (5 μg/kg per min, n=13). Among
other effects, levosimendan increased gastric mucosal flow, cre-
atinine clearance, and urinary output while it decreased lactate
concentrations.
Consensus Opinion on the Renal Effects of Levosimendan
in a Clinical Setting
Most reports on the effect of levosimendan indicate an im-
provement of renal function in heart failure, sepsis and cardiac
surgery settings (Table 2). However, caution should be applied
as study designs differed from randomized, controlled studies
to uncontrolled ones. These studies are mainly confined to
patients with severe systolic HF and some degree of renal
dysfunction, and provide additional information on renal bio-
markers and function. Importantly, in the largest HF study
(REVIVE I and II) no significant changes in the renal function
were detected. Data from the surgical setting are also hetero-
geneous, ranging from no effect in patients with normal renal
function to clinical benefit in those requiring mechanical assist
devices for post-cardiotomy HF. Larger studies in different
clinical settings (mainly acute HF, septic shock, cardiac sur-
gery) are warranted to clarify the renal effects of
levosimendan.
Potential Mechanisms of Renal Protection
The KATP channel opening effects of levosimendan in vascular
smooth muscle is linked to organ-preserving effects in several
preclinical and clinical investigations [6]. As these channels are
present in organ beds other than the myocardium, this mecha-
nism may offer organ protection extending beyond the heart.
Together with its hemodynamic effects, Morelli et al. [41] sug-
gested levosimendan may also be protective for lung, kidney,
liver, gastrointestinal mucosa, brain and vascular endothelium.
Timely intervention with levosimendan may reverse the on-
going processes of renal dysfunction through several protective
mechanisms involving macro- or microcirculation. Renal blood
flow depends on renal vascular resistance, as well as, arterial and
venous pressures. Of note, central venous pressure is an impor-
tant independent predictor of eGFR in patients with HF [42].





sections. RBF renal blood flow;
MAP mean arterial pressure; RPV
renal parenchymal volume; GFR
glomerular filtration rate
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When compared to traditional inotropes, levosimendan provides
functional improvement of the right ventricle and significant
reductions in right-sided pressures, including central venous
and pulmonary artery wedge pressures [43–45]. This potentially
alleviates the increased renal vein pressure that may impair renal
function through a decreased perfusion pressure and a decrease
in GFR.
Furthermore, Bragadottir et al. [33] found that levosimendan
induced a preglomerular vasodilation (with an increase in both
RBF and GFR), suggesting that the potential beneficial renal
effects of levosimendan in patients with heart failure and im-
paired renal function, may not only be caused by an increase in
cardiac output, but also by a specific renal vasodilatory action. In
fact, KATP channels are also present in afferent arterioles [46] and
may play a role in the effects of levosimendan on renal blood
flow (see Fig. 2). In contrast, in cardiac surgery patients, dopa-
mine dilates both pre- and postglomerular resistance vessels,
with a pronounced increase in renal blood flow but with no
change in GFR [47].
With regard to the microcirculation, levosimendan may aug-
ment renal perfusion via vasodilatation arising from its KATP
channel agonism. Furthermore, it may reverse angiotensin-2-
mediated mesangial cell contraction [14], thereby increasing
glomerular capillary surface area [48]. This provides a further
rationale for the use of levosimendan in septic shock where renal
vasoconstriction is mediated at least in part by angiotensin-2
[40]. Other potentially beneficial mechanisms within the kidney
relate to preconditioning, anti-inflammatory and anti-apoptotic
effects [6].
Future Studies
The panel agreed that it would be useful, although a very
demanding task, to compare systematically the renal effects
of other i.v. drugs used in acute cardiac care (in all settings)
such as recombinant natriuretic peptides, nitrates, other KATP
channels openers, catecholamines, and phosphodiesterase in-
hibitors (see the recent data associating milrinone to an in-
crease of acute kidney injury risk in cardiac surgery [49]).
Ideally, large randomized controlled trials seeking benefi-
cial renal effects of levosimendan in different clinical settings
should be performed.
In this regard, it is worth to mention that a 500-patient study
sponsored by the NIHR-EME program is shortly to commence
in the UK (led by Dr Anthony Gordon in conjunction with the
Imperial Clinical Trials Unit) assessing the role of
Levosimendan for the Prevention of Acute oRgan Dysfunction
in Sepsis (LeoPARDS). This double-blind randomised placebo-
controlled trial will test if levosimendan, when added to normal
care, can reduce multiple organ failure, which will then hope-
fully lead to better outcomes and survival rates for patients.
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